PhD Scientific Days 2024

Poster Session Q - Pathological and Oncological Sciences 2.

BRCA1/2 Mutations in Prostate Cancer: Association with Clinicopathological Parameters and Patients’ Survival

Előadó neve

Mr. Soós, Áron

Neptun code

S416UB

Előadó munkahelye

Department of Urology, Semmelweis University

Előadó telefonszáma

+36 30 591 9291

Előadó e-mail címe

soosaron2@gmail.com

Az előadás címe

BRCA1/2 Mutations in Prostate Cancer: Association with Clinicopathological Parameters and Patients’ Survival

Szerző(k) neve és munkahelye

Áron Soós¹, Anita Csizmarik¹, Erzsébet Rásó², Miklós Szűcs¹, Péter Nyirády¹, Tibor Szarvas^1,3

1: Department of Urology, Semmelweis University, Budapest, Hungary
2: Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary
3: Department of Urology, University of Duisburg-Essen and German Cancer Consortium (DKTK) - University Hospital Essen, Essen, Germany

Bemutatás módja

Poszter

Szekció

Poster Session Q - Pathological and Oncological Sciences 2.

Language of the presentation

Hungarian

Preferred session

Pathological and Oncological Sciences

Összefoglaló szövege

Introduction
Approximately 12% of metastatic prostate cancers (PC) harbour loss-of-function mutations in their BRCA1/2 genes. Patients with BRCA1/2 mutations exhibit reduced prognosis and different therapeutic sensitivity. PARP inhibitor (PARPi) therapy is now a targeted option for BRCA1/2-positive metastatic castration-resistant PC (mCRPC), while platinum chemotherapy maybe also effective in these cases. Current guidelines recommend BRCA1/2 testing for high-risk and particularly for metastatic PC.
Aims
Our aim was to provide an overview on the implementation of BRCA1/2 testing of PC patients in the Department of Urology, Semmelweis University. In addition, we assessed the association of BRCA1/2 mutations with clinical parameters, therapeutic sensitivity and survival of PC patients.
Methods
BRCA1/2 testing was performed from blood or tumor tissue using next generation sequencing (NGS) analyses as part of the clinical routine. As data collection is still ongoing, an interim statistical analysis was performed focusing on the BRCA1/2 genes using Chi2 test for paired comparisons and Kaplan-Meier survival curves with log-rank test for survival analysis.
Results
Between 03/2019 and 01/2024 BRCA1/2 tests were requested for 107 PCa patients. Six patients had local PC, 38 patients had metastatic hormone-sensitive PC and 63 patients had CRPC at the time of analysis. NGS was performed for 94 PC patients using prostate biopsy (n=43), transurethral prostate biopsy (n=6), radical prostatectomy specimen (n=21), lymph node biopsy (n=1), bone biopsy (n=1) or blood samples (n=22), while for 13 patients samples were not suitable for analyses. Of the 94 PC patients 16 (15%) harboured BRCA1/2 mutation (BRCA1 n=6; BRCA2 n=10). Patients’ age, ISUP grade and serum PSA levels at first diagnosis showed no significant difference between the mutated and wild-type groups. Out of 16 BRCA1/2 positive patients six received PARPi and three patients carboplatin therapy. We found no difference between BRCA1/2 positive and negative men in terms of OS.
Conclusion
To our knowledge, this is the first evaluation of BRCA1/2 testing in PC in Hungary. BRCA1/2 analysis is requested mostly in metastatic stages and in most cases the results were incorporated into the clinical decision-making. BRCA1/2 positive PC patients showed similar clinicopathological characteristics and OS to BRCA1/2 wild-types.

University

Semmelweis University

Supervisor

Tibor Szarvas / Anita Csizmarik

Publication of my abstract

I give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

7993

Start

16:30

End

16:33